NEW YORK (GenomeWeb News) – The UK’s Institute of Cancer Research will use Thermo Fisher Scientific’s proteomics technologies in an integrative network biology initiative, the company said today.

ICR will use Thermo’s TSQ Vantage triple quadrupole system, the Kingfisher Flex sample prep system, two LTQ Orbitrap Velos mass spectrometers, and other technologies, the company said.

The agreement includes lab equipment, protein reagents, mass spectrometry, RNA silencing, and related services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.